Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06619405 · ClinicalTrials.gov registry record · NA

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

A NA study of Age-related Macular Degeneration, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06619405 is a NA study of Age-related Macular Degeneration that is actively recruiting participants, run by Duke University. The registered enrollment target is 100 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06619405, a NA study of Age-related Macular Degeneration, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal is to conduct a cross-sectional, single timepoint study on older adults with early and intermediate AMD, and with subretinal drusenoid deposits (SDD), and those in normal health, establishing an association between dark adaptation and reading performance under dim illumination, both which depend on rod photoreceptors.

Interventions

  • DIAGNOSTIC_TEST Streetlab VR

Study Locations (1)

North Carolina

  • Duke Eye Center - Durham

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-08-15
Est. Completion 2027-12-31
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT06619405

The ClinicalTrials.gov registry entry for NCT06619405 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Streetlab VR is the first listed.

NCT06619405 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06619405 about?

NCT06619405 is a clinical study titled "AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance". The goal is to conduct a cross-sectional, single timepoint study on older adults with early and intermediate AMD, and with subretinal drusenoid deposits (SDD), and those in normal health, establishing an association between dark adaptation and reading performance under dim illumination, both which d...

What is the current status of trial NCT06619405?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-08-15. Estimated completion is 2027-12-31.

What conditions does trial NCT06619405 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

What interventions are being tested in trial NCT06619405?

The interventions under investigation include: Streetlab VR (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06619405?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06619405 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.